✨ Free AI Report
Selvita S.A.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Selvita S.A.
Company Research

Selvita S.A.: Business Overview, Financials & Competitive Analysis

Selvita is a leading European CRO supporting pharma and biotech companies with flexible, science-driven R&D services offering integrated or standalone solutions in drug discovery, preclinical studies, and GLP-complian...

Analyst-debate audio for Selvita S.A.

AskCyborg analysts argue the bull and bear cases for Selvita S.A. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Selvita offers comprehensive preclinical drug discovery and development services with strong market recovery momentum, strategic...

Read the full analyst-debate transcript →
Industry Pharmaceutical Contract Research Organization (CRO) / Contract Development and Manufacturing Organization (CDMO)
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Selvita S.A. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Selvita S.A. Overview

Pro stress-test →

Selvita is a leading European CRO supporting pharma and biotech companies with flexible, science-driven R&D services offering integrated or standalone solutions in drug discovery, preclinical studies, and GLP-compliant analytical development. The company helps accelerate new therapies by delivering high-quality data that enables smart decisions and faster time to market.

Strategic Profile

Pro stress-test →

Selvita develops dynamically, combining organic growth with acquisitions to deliver research solutions to partners globally. The drug development segment has grown to represent approximately 25% of revenue with 200 employees following the Pozlab acquisition, expanded services including therapeutic antibody discovery and development.

Competitive Landscape

Pro stress-test →

Selvita is one of the leading preclinical contract research organizations in Europe. Key competitors in the European CRO/CDMO space include Evotec, Eurofins Discovery, and Sygnature Discovery, with Selvita differentiating through integrated small molecule and biologic drug discovery services, growing CDMO capabilities via PozLab acquisition, and strategic focus on early-to-late stage development across therapeutic areas.

Industry Context

Selvita S.A. operates in Pharmaceutical Contract Research Organization (CRO) / Contract Development and Manufacturing Organization (CDMO).

Key facts

Founded: 2007 · Headquarters: Krakow, Poland · Employees: 950-1000 · Revenue: $95.5M · Market cap: $192M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Selvita S.A..

  • Big pharma customer revenues reached EUR 20.2 million (51% y/y increase) and now represent 26% of revenue, reinforcing foundation with long-term contracts.
  • Internal optimization initiatives expected to deliver EUR 6.4 million annual savings in 2026, with first effects visible in H2 2025 strengthening operating profit by EUR 0.5 million.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 20252024 full-year results show 11% backlog growth for 2025 and rebounding profitability in H2 2024 with 86% EBITDA growth
  • December 2024Hired Dr. Paul Overton as Chief Commercial Officer with 25+ years pharmaceutical/CRO industry experience
  • +2 moreTrack every material event for Selvita S.A. as it happens. Explore monitoring →
Get alerted when Selvita S.A. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Drug Discovery & CDMO ServicesEuropean drug discovery and development CRO with integrated services→Contract Research ServicesGlobal preclinical and analytical research services→Preclinical Drug DiscoveryMedicinal chemistry and drug discovery services→

Compare Selvita S.A. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Selvita S.A. operates in Pharmaceutical Contract Research Organization (CRO) / Contract Development and Manufacturing Organization (CDMO). See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Contract Research Organization (CRO) / Contract Development and Manufacturing Organization (CDMO) research →
NEW · MCP server

Ask your AI assistant about Selvita S.A.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Selvita S.A. and its top competitor on Cyborg Score”
“What did Selvita S.A. do this quarter?”
“Is Selvita S.A. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Selvita S.A. do?+
Selvita is a leading European CRO supporting pharma and biotech companies with flexible, science-driven R&D services offering integrated or standalone solutions in drug discovery, preclinical studies, and GLP-complian...
What is Selvita S.A.'s Cyborg Score?+
Selvita S.A. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Selvita S.A.'s main competitors?+
Named competitors include Drug Discovery & CDMO Services, Contract Research Services, Preclinical Drug Discovery. The full competitive landscape is in the AskCyborg report.
How can I get the full Selvita S.A. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Selvita S.A. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Selvita S.A. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.